 Mission Statement
:
We Help People Feel Better.
Our Objectives:
To create and provide to the world the most
technologically advanced and superior health
promoting nutritional supplements available.
To use the highest integrity, the best intentions, and the
customers'
health and well-being in the forefront of all our corporate actions.
Gematria Products
Inc. was incorporated in Carlsbad, CA on July 10, 1996 and since has
been diligently working on the R&D of a wide range of laser
enhanced nutritional supplements that are largely amino acid,
nucleotide, and vitamin based. We currently have 29 products in our
product repertoire.
To understand the
beginnings of Gematria Products Inc. and our patented laser
enhancement process, it is important to begin with Dr. Todd
Ovokaitys, CEO, MD (pulmonary & critical care specialist), and
product formulator and to discuss his work with the laser acoustic
resonance of molecular structure.
As to Dr. Todd's
(as he is called) formal academic background, he received BA and MD
degrees from Johns Hopkins University after acceptance into an
accelerated integrated medical training program. Following this
training he completed an Internship, Residency, and Chief Medical
Residency in the Georgetown University Hospital System. This was
followed by a two year Fellowship in Pulmonary and Intensive Care
Medicine, also at Georgetown University Hospital.
At Georgetown, Dr.
Todd participated in formal studies of T cell immune function after
harvesting lymphocytes from the lung via fiberoptic bronchoscopy. In
addition, this training involved intensive care of many persons
afflicted with HIV infection, as the lung is a common target
following the immunologic breakdown of this condition.
Aware of the
extreme limitations of treating HIV through ordinary conventional
means, I began a search for less intrusive solutions. The concept of
using the subtle differences of genetic organization between the
viral and human genomes was the launch point for exploring new
avenues of molecular resonance technologies. In concept, the slight
differences of resonance signatures between the viral and human
genomes could be used to selectively target and eliminate infected
parts of cells leaving uninfected normal cells unharmed.
After studying the
background work on the effects of electromagnetic radiation on
living systems, a colleague was located with the expertise to design
and build a fundamentally new laser electromagnetic resonance
technology. Scott Strachan, a Scottish physicist, electrical, and
chemical engineer took the basic concepts and reduced them to a
functional technology within 6 weeks. Among his accomplishments are
being an inventor of real time ultrasound and being the recipient of
the Enterprise Scotland Award from Prince Charles for development of
highly precise laser measurement instruments.
This new laser
optical technology has been patented worldwide as U.S. 6064500 and
worldwide patent WO09722022A1.
This invention is
formally described as a "holographic temporal displacement
prism for the non-fringing phase conjugate interference of
light." The new wave structure of light produced has a range of
physical properties that transcends several of the usual limits of
laser-molecular and laser-tissue interactions. When ordinary laser
light in the visible spectrum interacts with tissue there is intense
scattering such that a coherent signal cannot penetrate more than
5mm. Sparse constructive nodes are ultra-brief wave summation
signals that spark in and out of existence deeply in tissue or an
otherwise scattering medium, with 6-20cm projection even through
bone predicted. The duration of the pulse is just long enough to
excite specific desired molecular stimulation, yet brief enough not
to nonspecifically heat target molecular structures.
Global applications
patents have been submitted for "The Use of Sparse Constructive
Nodes (of electromagnetic energy) for the Selective Modulation of
Cell Surface Chemistry." This general applications patent
covers the use of the laser technology to activate and enhance
desired cell chemistries in vitro and in vivo. In addition this
patent also covers the use of the laser to activate or homogenize
the state of nutrients or pharmaceuticals to increase the specific
desired biological activity.
In addition to this
work, a recent randomized prospective, placebo controlled clinical
study suggests the potency and efficacy of laser-enhanced betaine (trimethylglycine)
in our HeartGems product. Over a three-month protocol of increasing
doses of an activated betaine and cofactor formula, the study showed
the following:
Subjects in the
treatment group showed a statistically significant drop in
homocysteine, a decrease suggesting a 25-30% reduction in cardiac
risk factors and an up to 15-20 year lowering of physiologic age
chemistry.
No reduction of homocysteine levels in the placebo group.
Treated subjects showed a highly statistically significant drop in
depression and somatization (body aches and pains) scores.
Subjects with autoimmune conditions such as lupus had remarkable
improvement in symptoms.
For the first time ever, treated subjects showed a highly
statistically significant reduction in human hostility levels. 
Click
below to view the entire
Gematria
Product Line
to where you were
|
